

# Initial Prior Authorization

## Universal States Mandate PANDAS PANS

### CD20-Directed Cytolytic Antibody

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

### CD20-Directed Cytolytic Antibody

Brand Name
Riabni
Rituxan
Ruxience
Truxima

## Coverage Criteria

### Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

Authorization may be granted when the patient has a diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.

### Pediatric acute onset neuropsychiatric syndrome

Authorization may be granted when the patient has a diagnosis of pediatric acute onset neuropsychiatric syndrome.

Reference number(s)
3117-A

## Autoimmune encephalitis

Authorization may be granted when the patient has a diagnosis of autoimmune encephalitis.

## Duration of Approval (DOA)

- 3117-A: DOA: 6 months

## References

1. Delaware House Bill 386. August 2018.
2. Illinois House Bill 2721. July 2017.
3. Illinois Senate Bill 101. June 2023.
4. New Hampshire House Bill 224. September 2019.
5. Minnesota Senate Bill 12a. May 2019.
6. Maryland Senate Bill 475. May 2020.
7. Maryland House Bill 820. May 2022.
8. Indiana House Bill 1372. May 2020.
9. Massachusetts Senate No. 2984. December 2020.
10. Arkansas Senate Bill 387. April 2021.
11. Arkansas Senate Bill 639. April 2021. M
12. Rhode Island H 7503. June 2022.
13. Oregon Senate Bill 628. May 2023.
14. Arkansas Senate Bill 181 and Amended Rule 127. October 2023.
15. Colorado House Bill 1382. June 2024.
16. California Assembly Bill 2105. September 2024.
17. Virginia H 1641. March 2025.
18. Louisiana House Bill 408. June 2025.